Brain exercises may boost aging minds: new study tests computerized training

NCT ID NCT04149457

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a computerized cognitive training program can improve brain health in adults aged 65 and older. Participants will use either a specially designed training program or casual video games for 30 minutes a day. The study measures changes in brain chemistry and cognitive function over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Computerized cognitive training exercises
What this could lead to
If effective, this program could offer a non-drug way to support brain health and slow age-related cognitive decline.
What could go wrong
This is a small, early-stage study. The training may not produce lasting benefits, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

93 people

The number who actually took part.

Started

Jul 2021

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Potential participant must be 65+ years old at the time of study screening. * Potential participant should achieve a score of ≥ 23 on the Montreal Cognitive Assessment (MoCA). * Potential participant must be likely able to compete all primary outcome measures in the judgment of the consenting study staff person. * Potential participant must demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study. * Potential participant must have the visual, auditory, and motors capacity to use the computerized intervention in the judgment of the consenting study staff person. * Potential participant must already have, be willing to obtain, or be willing to travel to locations with WiFi connectivity to complete intervention activities. * Potential participant must be able to communicate in either English or French. Exclusion Criteria: * Potential participant should not have an existing diagnosis of major or minor neurocognitive disorder at screening. * Potential participants with active suicidal ideation with specific plan and intent or suicide-related behaviors within 2 months of consent as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) * Potential participant should not have a Geriatric Depression Scale (GDS) score of \>10. * Potential participant should not have been treated within 5 years of the date of consent with a computer-based cognitive training program manufactured by Posit Science. * Potential participant should not be participating in a concurrent clinical trial (involving an investigational pharmaceutical, behavioral treatment, medical device or other) that, in the judgment of the Site Principal Investigator, could affect the outcome of this study. * Potential participant may not be pregnant and should not have claustrophobia or implantation with any medical devices above the waist that may concentrate radio frequency fields, or have other medical issues that may frustrate participation in MRI imaging procedures. * Potential participant should not have medical illnesses deemed to interfere with participation in study activities and/or unstable and/or untreated conditions that may affect cognition, including substance abuse/dependence disorders, drugs that interfere with cholinergic function, ongoing chemotherapy or other cancer treatment. * Potential participant who shows signs of intoxication due to current substance abuse (including alcohol and/or illegal drugs) will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • McGill University

    Montreal, Quebec, H3A 2B4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.